NZ752214A - Arsenic compositions - Google Patents

Arsenic compositions

Info

Publication number
NZ752214A
NZ752214A NZ752214A NZ75221417A NZ752214A NZ 752214 A NZ752214 A NZ 752214A NZ 752214 A NZ752214 A NZ 752214A NZ 75221417 A NZ75221417 A NZ 75221417A NZ 752214 A NZ752214 A NZ 752214A
Authority
NZ
New Zealand
Prior art keywords
arsenic trioxide
arsenic
compositions
nahas2o4
realisation
Prior art date
Application number
NZ752214A
Inventor
Malvin Eutick
Original Assignee
Eupharma Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016904945A external-priority patent/AU2016904945A0/en
Application filed by Eupharma Pty Ltd filed Critical Eupharma Pty Ltd
Publication of NZ752214A publication Critical patent/NZ752214A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention is predicated on the realisation that problems with the poor water solubility of arsenic trioxide and the extreme difficulty in dissolving arsenic trioxide in anything other than a very basic solution, could be overcome by forming a much more soluble diarsenic tetraoxide, including the compound NaHAs2O4, prior to its delivery to a patient. Pharmaceutical compositions with such compounds and their use in the treatment of cancers is disclosed.
NZ752214A 2016-12-01 2017-08-02 Arsenic compositions NZ752214A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2016904945A AU2016904945A0 (en) 2016-12-01 Arsenic compositions
PCT/AU2017/050807 WO2018098519A1 (en) 2016-12-01 2017-08-02 Arsenic compositions

Publications (1)

Publication Number Publication Date
NZ752214A true NZ752214A (en) 2022-11-25

Family

ID=62240940

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ752214A NZ752214A (en) 2016-12-01 2017-08-02 Arsenic compositions

Country Status (21)

Country Link
US (1) US11241453B2 (en)
EP (1) EP3548044B1 (en)
JP (2) JP7080230B2 (en)
KR (1) KR102487884B1 (en)
CN (1) CN109952105A (en)
AU (1) AU2017368444B9 (en)
BR (1) BR112019007498A2 (en)
CA (1) CA3041357A1 (en)
CL (1) CL2019001422A1 (en)
DK (1) DK3548044T3 (en)
ES (1) ES2964979T3 (en)
IL (1) IL265986B (en)
MX (1) MX2019006107A (en)
NZ (1) NZ752214A (en)
PE (1) PE20191544A1 (en)
PL (1) PL3548044T3 (en)
SA (1) SA519401885B1 (en)
SG (1) SG11201903064SA (en)
TW (1) TWI808060B (en)
WO (1) WO2018098519A1 (en)
ZA (1) ZA201902156B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3490939B1 (en) 2016-08-01 2021-11-03 Veolia Water Solutions & Technologies Support Process for removing silica from produced water
MX2019006107A (en) * 2016-12-01 2019-08-21 Eupharma Pty Ltd Arsenic compositions.
WO2022180582A1 (en) * 2021-02-26 2022-09-01 Intas Pharmaceuticals Ltd. Oral pharmaceutical composition of arsenic trioxide
JP2022151442A (en) * 2021-03-26 2022-10-07 均 石井 Agents for treating leukemia

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2080004A (en) * 1933-05-17 1937-05-11 Frederick E Dearborn Double salt of copper arsenite and a copper salt of an unsaturated fatty acid and process of making the same
US3280046A (en) 1963-03-27 1966-10-18 Dow Chemical Co Polyol ether resins and utility
AU751932B2 (en) 1997-10-15 2002-08-29 Polarx Biopharmaceuticals, Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
EP1964557B1 (en) 1997-11-10 2013-01-02 Memorial Sloan-Kettering Cancer Center Process for producing arsenic trioxide formulations
CN1471925A (en) * 2002-08-02 2004-02-04 丛繁滋 Arsenic contained composition for directly hard tumour medoicine feed, preparation, preparing method thereof
US7521071B2 (en) 2002-10-09 2009-04-21 Versitech Limited Formulation of oral compositions comprising arsenic trioxide and methods of use thereof
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US20090246291A1 (en) * 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
CN102060722B (en) * 2009-05-01 2014-06-11 常州高新技术产业开发区三维工业技术研究所有限公司 Arsenic compound and preparation method and use thereof
EP2359812A1 (en) 2010-01-18 2011-08-24 Cephalon France Oral lyophilised compositions
CN105435228B (en) * 2014-08-14 2020-08-07 中国科学院上海营养与健康研究所 New anti-tumor application of arsenic trioxide and anti-tumor preparation
AU2016212703B2 (en) * 2015-01-29 2017-12-07 Eupharma Pty Ltd Compositions containing arsenic and their use in methods of treatment
JP6928768B2 (en) 2015-02-01 2021-09-01 サイロス・ファーマシューティカルズ・インコーポレイテッドＳｙｒｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． High surface area lyophilized composition containing arsenic for oral administration of patients
MX2019006107A (en) * 2016-12-01 2019-08-21 Eupharma Pty Ltd Arsenic compositions.

Also Published As

Publication number Publication date
ZA201902156B (en) 2021-01-27
KR102487884B1 (en) 2023-01-11
AU2017368444B9 (en) 2020-07-02
CN109952105A (en) 2019-06-28
KR20190089865A (en) 2019-07-31
SA519401885B1 (en) 2023-12-24
AU2017368444A1 (en) 2019-04-18
SG11201903064SA (en) 2019-05-30
PE20191544A1 (en) 2019-10-24
TW201821087A (en) 2018-06-16
PL3548044T3 (en) 2024-03-04
BR112019007498A2 (en) 2019-07-02
MX2019006107A (en) 2019-08-21
JP7419415B2 (en) 2024-01-22
TWI808060B (en) 2023-07-11
ES2964979T3 (en) 2024-04-10
WO2018098519A1 (en) 2018-06-07
EP3548044A1 (en) 2019-10-09
JP7080230B2 (en) 2022-06-03
JP2020500845A (en) 2020-01-16
US20200016196A1 (en) 2020-01-16
AU2017368444B2 (en) 2020-04-30
EP3548044A4 (en) 2020-07-22
IL265986A (en) 2019-06-30
DK3548044T3 (en) 2023-12-11
CL2019001422A1 (en) 2019-08-02
CA3041357A1 (en) 2018-06-07
EP3548044B1 (en) 2023-09-20
IL265986B (en) 2022-09-01
US11241453B2 (en) 2022-02-08
JP2022069485A (en) 2022-05-11

Similar Documents

Publication Publication Date Title
SA519401885B1 (en) Arsenic Compositions
MX2016016666A (en) Boronic acid derivatives and therapeutic uses thereof.
MX2016015093A (en) Boronic acid derivatives and therapeutic uses thereof.
TN2017000452A1 (en) Compositions of obeticholic acid and methods of use
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
MX2018001721A (en) 5-bromo-2,6-di-(lh-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer.
NZ733174A (en) Quinazoline derivatives used to treat hiv
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
MX2015008627A (en) Boronic acid derivatives and therapeutic uses thereof.
PH12018502497A1 (en) Adenosine derivatives for use in the treatment of cancer
MX2016011897A (en) Compositions of selenoorganic compounds and methods of use thereof.
EA033446B1 (en) Heterocyclic compound for treating macular degeneration and/or stargardt's disease
EA201790726A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ULCERAL COLITIS
MX361642B (en) Cationic antiseptic compositions.
UY35735A (en) DISTRICTED TRIFLUOROMETILPIRIMIDINONES AND ITS USE
PH12018501709A1 (en) Naphthridinedione derivatives
EA032654B9 (en) [1,2,4]TRIAZOLO[4,3-b]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES
WO2016040814A3 (en) Disulfide polymers and methods of use
MX2018007112A (en) Fast dissolving peroxymonosulfate composition.
UA116913C2 (en) Process for the preparation of xanthohumol
WO2015160470A3 (en) Nadph production by the 10-formyl-thf pathway, and its use in the diagnosis and treatment of disease
MX2015012720A (en) Base addition salts of nitroxoline and uses thereof.
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction
MX2017009659A (en) Compositions containing arsenic and their use in methods of treatment.
WO2016057660A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2024 BY SPRUSON + FERGUSON PTY LTD

Effective date: 20230703